San Francisco startup Framework Therapeutics is usually engaged on an oral, after-day by day GLP-1 drug known as GSBR-1290—the drug surpassed Wall Road’s expectations in June when a mid-stage research showed common weight loss of about six% and it ideas to start A different mid-stage trial toward the tip of the year—that founder and CEO Raymo